This session will describe the biological and social determinants of health that contribute to ethnic and racial disparities in health and health care; identify the racial and ethnic disparities that have been documented in patients with primary HCC and liver transplantation; and list strategies to prevent viral hepatitis, reduce deaths and decrease health disparities due to HBV and HCV in the U.S.Stephen Thomas Fasiha Kanwal Fasiha Kanwal, MD, MSHS, AGAF, FAASLD is a professor of medicine and chief of Gastroenterology and Hepatology at Baylor College of Medicine.

Kim Loh, Shanna Tam, Lisa Murray‐Segal, Kevin Huynh, Peter J. Meikle, John W. Scott, Bryce van Denderen, Zhiping Chen, Rohan Steel, Nicholas D. LeBlond, Leah A. Burkovsky, Conor O’Dwyer, Julia R.C. Nunes, Gregory R. Steinberg, Morgan D. Fullerton, Sandra Galic, Bruce E. Kemp – 12 November 2018 – Adenosine monophosphate–activated protein kinase (AMPK) regulates multiple signaling pathways involved in glucose and lipid metabolism in response to changes in hormonal and nutrient status.

Chronic HBV (CHB) infection follows a dynamic course with multiple phases of disease with various durations.  ALT flares during CHB can be challenging for clinicians to manage.  In some settings ALT flares herald a transition from active to inactive disease and thus are considered to be beneficial. In other scenarios, they may indicate aggressive inflammatory liver disease than can lead to progressive liver injury or even fulminant hepatic failure.

This program has been designed to improve the diagnosis, pharmacologic treatment and management of patients with chronic liver disease. The current data is highlighted to support effective and efficient patient-centered care. Attendees will gain the ability to utilize medical knowledge and research to provide quality, evidence-based care and to enhance interdisciplinary collaboration to improve health outcomes.Lisa M.

This program will describe the molecular mechanisms and rationale for novel systemic therapy agents targeting signaling pathways and immune mechanisms that have been recently approved for the treatment of hepatocellular carcinoma. The program will also cover the roles of new agents in the current AASLD guidelines for treatment of hepatocellular carcinoma.Jessica Zucman-Rossi Augusto Villanueva Augusto Villanueva is Assistant Professor in the Liver Cancer Program (Icahn School of Medicine at Mount Sinai, New York).

This program will provide practicing clinicians with an update on recent changes in the epidemiology of alcoholic liver disease, advances in understanding of its pathophysiology and the impact of social policies on alcohol use disorders. The program will then present advances in the treatment of alcohol abuse and alcoholic liver disease, including novel models of multidisciplinary care for these patients.Jessica L. Mellinger Ian Gilmore Robert Weinrieb Vijay Shah

This activity will provide updates and practical guidance for care providers dealing with 3 common and or difficult to manage conditions. The knowledge will improve practitioner's performance as care providers and will improve patient outcomes.Cynthia Levy Cynthia Levy, MD, FAASLD is a Professor of Medicine in the Division of Digestive Health and Liver Diseases and is the Associate Director of the Schiff Center for Liver Diseases at the University of Miami. She was awarded the Arthur Hertz Endowed Chair in Liver Diseases. Dr. Levy received her M.D.

This lecture will examine the intersection of hepatobiliary neoplasia and liver transplantation to highlight what is currently working well, including liver transplantation for early stage hepatocellular carcinoma and hilar cholangiocarcinoma, as well as less common indications such as euroendocrine tumors. The speaker will highlight continued challenges, particularly related to overall disease burden, organ availability and allocation policy, and transplantation for more advanced tumors.

Hans Clevers, MD, PhD, will describe his groundbreaking research in the development of organoid technology and how it can be applied to liver and biliary disease. His lecture will focus on organoids developed from bile duct cells and hepatocytes, and applications for disease modeling in cancer, hereditary disease and regenerative medicine strategies.Hans Clevers

This half-day program provides an overview of both current and emerging therapies for common liver diseases. Additionally, it will enhance knowledge around diagnostics and highlight the roles of collaborating professionals.Yuko Kono John E. Eaton Dr. John Eaton is a transplant Hepatologist with a clinical and research focus on cholestatic liver diseases with an emphasis on primary sclerosing cholangitis (PSC) and related comorbid conditions. His clinical practice involves seeing a large volume of patients with PSC and PSC complicated by cholangiocarcinoma. Dr.